One-year evolution of DLCO changes and respiratory symptoms in patients with post COVID-19 respiratory syndrome.
DLCO
Long-COVID
Post-acute sequelae of SARS-CoV-2 infection
Respiratory symptoms
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
12
12
2021
accepted:
10
01
2022
pubmed:
22
1
2022
medline:
26
3
2022
entrez:
21
1
2022
Statut:
ppublish
Résumé
During a follow-up program of patients admitted for COVID-19 at our non-ICU Unit, we found that 37% of them had decreased diffusing lung capacity for carbon monoxide (DLCO) 3-6 months after discharge. This prospective observational study aimed to evaluate the evolution of changes in DLCO and respiratory symptoms at the 1-year follow-up visit. Seventeen (mean age 71 years; 8 males) of 19 eligible patients (DLCO < 80% of predicted at the 3-6 months follow-up visit) completed the 1-year follow-up visit. One patient refused to participate and 1 patient had died 3 months earlier from myocardial infarction. The visit included a self-reported structured questionnaire, physical exam, blood tests, ECG, and spirometry with DLCO. Mean DLCO was significantly improved at the 1-year visit (from 64% of predicted at 3-6 months to 74% of predicted at 1 year; P = 0.003). A clinically significant increase in DLCO (10% or greater) was observed in 11 patients (65%) with complete normalization (> 80% of predicted) in 6 (35%); in the other 6 (35%) it remained unchanged. The prevalence of exertional dyspnea (65-35%, P = 0.17), cough (24-18%, P = 1), and fatigue (76-35%, P = 0.04) decreased at the 1-year visit. These results suggest that DLCO and respiratory symptoms tend to normalize or improve 1 year after hospitalization for COVID-19 in most patients. However, there is also a non-negligible number of patients (about one-third) in whom respiratory changes persist and will need prolonged follow-up.
Identifiants
pubmed: 35061232
doi: 10.1007/s15010-022-01755-5
pii: 10.1007/s15010-022-01755-5
pmc: PMC8777423
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
513-517Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397:220–32. https://doi.org/10.1016/S0140-6736(20)32656-8 .
doi: 10.1016/S0140-6736(20)32656-8
pubmed: 33428867
pmcid: 7833295
Fortini A, Torrigiani A, Sbaragli S, et al. COVID-19: persistence of symptoms and lung alterations after 3–6 months from hospital discharge. Infection. 2021;49:1007–15. https://doi.org/10.1007/s15010-021-01638-1 .
doi: 10.1007/s15010-021-01638-1
pubmed: 34091869
pmcid: 8179958
Jiang DH, Roy DJ, Gu BJ, Hassett LC, McCoy RG. Postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection: a state-of-the-art review. JACC Basic Transl Sci. 2021;6:796–811. https://doi.org/10.1016/j.jacbts.2021.07.002 .
doi: 10.1016/j.jacbts.2021.07.002
pubmed: 34541421
pmcid: 8442719
Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26:948–68. https://doi.org/10.1183/09031936.05.00035205 .
doi: 10.1183/09031936.05.00035205
pubmed: 16264058
Gruet M. Fatigue in chronic respiratory diseases: theoretical framework and implications for real-life performance and rehabilitation. Front Physiol. 2018;9:1285. https://doi.org/10.3389/fphys.2018.01285 (Published 2018 Sep 19).
doi: 10.3389/fphys.2018.01285
pubmed: 30283347
pmcid: 6156387
Wu X, Liu X, Zhou Y, et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. 2021;9:747–54. https://doi.org/10.1016/S2213-2600(21)00174-0 .
doi: 10.1016/S2213-2600(21)00174-0
pubmed: 33964245
pmcid: 8099316
Huang L, Yao Q, Gu X, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. 2021;398:747–58. https://doi.org/10.1016/S0140-6736(21)01755-4 .
doi: 10.1016/S0140-6736(21)01755-4
pubmed: 34454673
pmcid: 8389999
Becker C, Beck K, Zumbrunn S, et al. Long COVID 1 year after hospitalisation for COVID-19: a prospective bicentric cohort study. Swiss Med Wkly. 2021;151:w30091. https://doi.org/10.4414/smw.2021.w30091 .
doi: 10.4414/smw.2021.w30091
pubmed: 34694106
Vianello A, Guarnieri G, Braccioni F, et al. The pathogenesis, epidemiology and biomarkers of susceptibility of pulmonary fibrosis in COVID-19 survivors. Clin Chem Lab Med. 2021. https://doi.org/10.1515/cclm-2021-1021 (published online ahead of print, 2021 Nov 16).
doi: 10.1515/cclm-2021-1021
pubmed: 34783228
Spagnolo P, Balestro E, Aliberti S, et al. Pulmonary fibrosis secondary to COVID-19: a call to arms? Lancet Respir Med. 2020;8:750–2. https://doi.org/10.1016/S2213-2600(20)30222-8 .
doi: 10.1016/S2213-2600(20)30222-8
pubmed: 32422177
pmcid: 7228737
Boehm A, Luger AK, Schmitz K, et al. A spark of hope: histopathological and functional recovery after critical COVID-19. Infection. 2021. https://doi.org/10.1007/s15010-021-01678-7 (published online ahead of print, 2021 Aug 25).
doi: 10.1007/s15010-021-01678-7
pubmed: 34435313
pmcid: 8386898
Zhang P, Li J, Liu H, et al. Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study. Bone Res. 2020;8:8. https://doi.org/10.1038/s41413-020-0084-5 (published correction appears in Bone Res. 2020 Sep 21;8(1):34; Published 2020 Feb 14).
doi: 10.1038/s41413-020-0084-5
pubmed: 32128276
pmcid: 7018717